التفاصيل البيبلوغرافية
| العنوان: |
The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL-Mediated Apoptosis. |
| المؤلفون: |
BROOKS, ALAN D., RAMIREZ, TERESA, TOH, UHI, ONKSEN, JENNIFER, ELLIOTT, PETER J., MURPHY, WILLIAM J., SAYERS, THOMAS J. |
| المصدر: |
Annals of the New York Academy of Sciences; 2005, Vol. 1059 Issue 1, p160-167, 8p |
| مصطلحات موضوعية: |
CANCER, BREAST tumors, CANCER cells, CELLULAR pathology, COLON cancer |
| مستخلص: |
On testing a panel of different human cancer cell lines, we observed that the proteasome inhibitor bortezomib could dramatically sensitize some lines to the apoptotic effects of Apo2L/TRAIL. Certain renal, colon, or breast tumor cell lines were dramatically sensitized, whereas other tumor lines from the same tissue of origin remained resistant. This sensitization did not correlate with either the p53 status of the individual tumor cell lines or their intrinsic sensitivity to Apo2L/TRAIL. Colon cancer cell lines lacking p53 or Bax were sensitized by bortezomib, suggesting that neither p53 nor Bax levels were crucial for sensitization. Although the molecular basis of bortezomib sensitization of tumor cells to Apo2L/TRAIL remains to be determined, this combination can have an enhanced apoptotic effect over either agent alone for certain human cancer cells. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of the New York Academy of Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
